Simulations Plus, Inc. · NASDAQ:SLP

Simulations Plus — Q3 FY2023 Earnings Presentation

24 slides from Simulations Plus's earnings presentation, Jul 6, 2023

  1. Slide 1: Earnings Call – Q3 - FY23

    Slide 1: Earnings Call – Q3 - FY23

    Earnings Call – Q3 - FY23 July 6, 2023 1

  2. Slide 2: Safe Harbor Statement

    Slide 2: Safe Harbor Statement

    Safe Harbor Statement With the exception of historical information, the matters discussed in this presentation are forward- looking statements that involve a number of risks and uncertainties. Words like “believe,” “expect” and “anticipate” mean that these are our best estimates as of this writing,

  3. Slide 3: Third Quarter Highlights

    Slide 3: Third Quarter Highlights

    Third Quarter Highlights $16MRevenue $0.20 Diluted EPS 40% Adj. EBITDA as % $16M Backlog of Revenue ▪ Third quarter results in line with guidance ▪ Business Highlights ▪ Revenue seasonality impacted by shift in software renewal timing as expected ▪ Underlying market conditions continue as experience

  4. Slide 4: Third Quarter Software Highlights

    Slide 4: Third Quarter Software Highlights

    Third Quarter Software Highlights General ▪ Overall software revenue growth of 10% ▪ Renewal pattern and revenue seasonality shifting as anticipated ▪ Continued market spending cautiousness ▪ University+ program has 299 individual licenses across 56 countries ▪ Good yield on price increase GastroPlu

  5. Slide 5: Third Quarter Services Highlights

    Slide 5: Third Quarter Services Highlights

    Third Quarter Services Highlights General ▪ Overall services revenue growth 5% ▪ Total backlog $15.7M – projects to be performed within 12 months decreased from 80% to 77% ▪ Successful recruiting quarter (3 new hires, 10 YTD) ▪ 212 total projects worked on during the quarter PKPD +2% ▪ Higher margin

  6. Slide 6: Capital Allocation Strategy Update

    Slide 6: Capital Allocation Strategy Update

    Capital Allocation Strategy Update ▪ Product R&D ▪ Acquisitions ▪ Employee Recruiting and ▪ Strategic investments and INTERNAL CORPORATE Retention INVESTMENT DEVELOPMENT partnerships ▪ Enterprise Technologies ▪ Immunetrics acquisition consummated in Q4 ▪ Maintain current level ▪ $50M share repurchas

  7. Slide 7: Immunetrics Acquisition | June 2023

    Slide 7: Immunetrics Acquisition | June 2023

    Immunetrics Acquisition | June 2023 Increases breadth and depth of QSP expertise and range of therapeutic applications Rationale Terms ▪ Immunetrics is a modeling and simulation company focused on ▪ Paid Immunetrics shareholders cash consideration of $15.5 accelerating drug development in oncology,

  8. Slide 8: Maintaining FY23 Guidance

    Slide 8: Maintaining FY23 Guidance

    Maintaining FY23 Guidance Total Revenue $59.3M to $62.0M Total Revenue Growth 10% to 15% Software Revenue Mix 60% to 65% Services Revenue Mix 35% to 40% Diluted EPS $0.63 to $0.67 (excl. $0.09 M&A expense) (Q423 Immunetrics impact: due to timing of close and seasonality, revenue will be positive but

  9. Slide 9: Financial Results

    Slide 9: Financial Results

    Financial Results

  10. Slide 10: Revenue - Q3

    Slide 10: Revenue - Q3

    Revenue - Q3 (in millions) 3Q23 Mix 3Q22 Mix +9% +10% +5% Total Revenue Software Revenue Services Revenue 10

  11. Slide 11: Revenue - YTD

    Slide 11: Revenue - YTD

    Revenue - YTD (in millions) FY23 Mix FY22 Mix +4% +2% +9% Total Revenue Software Revenue Services Revenue 11

  12. Slide 12: Gross Margin Trends - Q3

    Slide 12: Gross Margin Trends - Q3

    Gross Margin Trends - Q3 90% —> owe eo 83% 81% => aoe C= 66% 63% —o— 63% — —o 3Q21 3Q22 3Q23 =@ Software -@®=Services =@= Total 12

  13. Slide 13: Gross Margin Trends - YTD

    Slide 13: Gross Margin Trends - YTD

    Gross Margin Trends - YTD 92% 89% o> ore io 81% 81% 79% —® = J = 66% 62% 62% e —o— FY21 FY22 FY23 =@ Software -@®=Services =@= Total 13

  14. Slide 14: Software Revenue by Product

    Slide 14: Software Revenue by Product

    Software Revenue by Product Q3 FY23 YTD FY23 GastroPlus® GastroPlus® MonolixSuite® MonolixSuite® ADMET Predictor® ADMET Predictor® Other Other Software Product as % of Software Revenue 14

  15. Slide 15: Software Performance Metrics - Q3

    Slide 15: Software Performance Metrics - Q3

    Software Performance Metrics - Q3 Commercial Customers Avg. Revenue per Customer Renewal Rates (in thousands) 15

  16. Slide 16: Software Performance Metrics - YTD

    Slide 16: Software Performance Metrics - YTD

    Software Performance Metrics - YTD Commercial Customers Avg. Revenue per Customer Renewal Rates (in thousands) 16

  17. Slide 17: Services Revenue by Type

    Slide 17: Services Revenue by Type

    Services Revenue by Type Q3 FY23 YTD FY23 PKPD PKPD QSP/QST QSP/QST PBPK PBPK Other Other Services Type as % of Services Revenue 17

  18. Slide 18: Services Performance Metrics

    Slide 18: Services Performance Metrics

    Services Performance Metrics Total Projects Backlog 18

  19. Slide 19: Income Statement Summary - Q3

    Slide 19: Income Statement Summary - Q3

    Income Statement Summary - Q3 (in millions, except Diluted EPS) 3Q23 % of Rev 3Q22 % of Rev Revenue $16.2 100% $15.0 100% Revenue growth 9% 17% Gross profit 13.3 82% 12.4 83% R&D 0.9 6% 0.7 4% SG&A 8.2 51% 6.8 45% Total operating exp 9.2 57% 7.5 50% Income from operations 4.1 25% 4.9 33% Income befo

  20. Slide 20: Income Statement Summary - YTD

    Slide 20: Income Statement Summary - YTD

    Income Statement Summary - YTD (in millions, except Diluted EPS) 3Q23 % of Rev 3Q22 % of Rev Revenue $43.9 100% $42.2 100% Revenue growth 4% 15% Gross profit 35.7 81% 34.0 81% R&D 3.4 8% 2.4 6% SG&A 23.3 53% 17.4 41% Total operating exp 26.7 61% 19.8 47% Income from operations 9.0 20% 14.2 34% Incom

  21. Slide 21: Balance Sheet Summary

    Slide 21: Balance Sheet Summary

    Balance Sheet Summary (in millions) May 31, 2023 August 31, 2022 Cash and short-term investments $122.4 $128.2 Total current assets $137.3 146.8 Total assets $179.1 $188.4 Current liabilities 9.0 7.7 Long-term liabilities 0.7 2.4 Total liabilities 9.7 10.1 Shareholders’ equity 169.4 178.2 Total liab

  22. Slide 22: Conclusion

    Slide 22: Conclusion

    Conclusion CONTINUED LEADERSHIP POSITION IN BIOSIMULATION MARKET Delivering on our Enhancing our client facing commitment to scientific Challenges being addressed Focus on Capital Allocation capabilities leadership • Internal R&D investment • Growth and maturity of • Software renewal timing • ASR pr

  23. Slide 23: Questions

    Slide 23: Questions

    Questions 23

  24. Slide 24: Simulations Plus

    Slide 24: Simulations Plus

    iS]+ SimulationsPlus

Source: Internet Archive copy of simulations-plus.com

More decks from Simulations Plus, Inc.

All 167 Simulations Plus decks